Matthew S. Waitkus

Assistant Professor at Neurosurgery, Duke University3 Followers

A trusted voice in discussions about neurobiology and cancer research, Matthew S. Waitkus serves as an Assistant Professor in Neurosurgery and Pathology at Duke University. With a profound commitment to advancing the understanding of malignant brain tumors, he is also a valued member of the Preston Robert Tisch Brain Tumor Center at Duke. His work is pivotal in exploring the molecular biology underlying these complex conditions, aiming to develop innovative therapeutic strategies. Dr. Waitkus's academic journey is marked by a Ph.D. from Cleveland State University, where he honed his expertise in neurobiology, and an M.S. from The Ohio State University College of Medicine, which laid the foundation for his career in medical research. His educational background has equipped him with a robust understanding of the intricate mechanisms of cancer biology, which he applies to his research endeavors. At Duke University, Dr. Waitkus is actively involved in both teaching and research, mentoring the next generation of scientists and clinicians. His research interests are centered around neurobiology, cancer, and brain tumors, with a particular focus on the genetic and epigenetic factors that drive tumor progression. Through his work, he aims to contribute to the development of targeted therapies that can improve patient outcomes and enhance the quality of life for those affected by brain tumors.

Research Interests

Neurobiology Cancer biology Malignant brain tumors Molecular biology Genetic factors Epigenetic factors Tumor progression Targeted therapies

Publications

1 - Abstract 1261: Mutant IDH-mediated suppression of the Th17 lineage in glioma: Biologic impact and therapeutic potential,Cancer Research

Nathan M. Reynolds , Ashleigh J. Soedel , Ximena Bustamante-Marin , Emily Z. Miller , Paula K. Greer , David M. Ashley , Yiping He , Matthew S. Waitkus , Christopher J. Pirozzi ,

, 1261-1261, 2023-04-04

2 - Abstract 3143: A bioinformatic pipeline for identifying change-of-metabolic-function cancer mutations,Cancer Research

Kevin J. Tu , Bill H. Diplas , Joshua A. Regal , Matthew S. Waitkus , Christopher J. Pirozzi , Zachary J. Reitman ,

, 3143-3143, 2023-04-04

3 - Abstract 4924: Alternative lengthening of telomeres is associated with hypersensitivity to topoisomerase 1 inhibition in glioblastoma xenograft models,Cancer Research

Stephen T. Keir , Heng Liu , Justin T. Low , Christopher J. Pirozzi , Nathan Reynolds , Eric S. Lipp , Annick Desjardins , Henry S. Friedman , Mustafa Khasraw , Darell D. Bigner , David M. Ashley , Matthew S. Waitkus ,

, 4924-4924, 2023-04-04

4 - Abstract 5496: Multi-omic spatial analysis of the tumor microenvironment in gliomas,Cancer Research

Dmytro Klymyshyn , Vaibhav Jain , Lauren Whaley , Emily Hocke , Bassem Ben Cheikh , Alan Smith , Karen Abramson , Nadine Nelson , Diane Satterfield , Elizabeth Thomas , Giselle Lopez , Seetha Hariharan , Michael Brown , Niyati Jhaveri , Roger McLendon , David Ashley , Matthew Waitkus , Simon Gregory ,

, 5496-5496, 2024-03-22

5 - Abstract 5821: The role of SMARCAL1 loss-of-function mutations in glioblastoma telomere maintenance,Cancer Research

Heng Liu , Cheng Xu , Lee H. Chen , Bill H. Diplas , Jinjie Ling , Paula K. Greer , Martin Roskoski , Stephen T. Keir , David M. Ashley , Hai Yan , Matthew S. Waitkus ,

, 5821-5821, 2020-08-15

6 - Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells,Neuro-Oncology

Heng Liu , Cheng Xu , Bill H Diplas , Alexandrea Brown , Laura M Strickland , Haipei Yao , Jinjie Ling , Roger E McLendon , Stephen T Keir , David M Ashley , Yiping He , Matthew S Waitkus ,

, 1563-1575, 2023-01-23

7 - DNAR-07. MOLECULAR BIOMARKERS ASSOCIATED WITH TARGETED DISRUPTION OF ALTERNATIVE LENGTHENING OF TELOMERES IN ATRX-DEFICIENT GLIOMA MODELS,Neuro-Oncology

Matthew Waitkus , Michael Brown , Christopher Pirozzi , Nathan Reynolds , Alexandrea Brown , Laura Strickland , Zachary Reitman , Steve Keir , Mustafa Khasraw , David Ashley ,

, v99-v99, 2023-11-01

8 - DNAR-08. THE ROLE OF SMARCAL1 AS A SYNTHETIC LETHAL VULNERABILITY IN ATRX-DEFICIENT GLIOMAS,Neuro-Oncology

Matthew Waitkus , Heng Liu , Alexandrea Brown , Laura Strickland , Taher Khambati , Casey Fraley , Bill Diplas , Stephen Keir , David Ashley ,

, vii91-vii92, 2022-11-01

9 - Mitogen-Activated Protein Kinase Phosphatase-1 Promotes Neovascularization and Angiogenic Gene Expression,Arteriosclerosis, Thrombosis, and Vascular Biology

Joel D. Boerckel , Unnikrishnan M. Chandrasekharan , Matthew S. Waitkus , Emily G. Tillmaand , Rebecca Bartlett , Paul E. DiCorleto ,

, 1020-1031, 2014-05-01

10 - Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells,

Heng Liu , Cheng Xu , Bill H. Diplas , Alexandrea Brown , Laura M. Strickland , Jinjie Ling , Roger E. McLendon , Stephen T. Keir , David M. Ashley , Yiping He , Matthew S. Waitkus ,

, 2022-09-19

11 - CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP,Molecular Cancer Research

Casey J. Moure , Bill H. Diplas , Lee H. Chen , Rui Yang , Christopher J. Pirozzi , Zhaohui Wang , Ivan Spasojevic , Matthew S. Waitkus , Yiping He , Hai Yan ,

, 2042-2050, 2019-10-01

12 - TMIC-07. MUTANT IDH-MEDIATED SUPPRESSION OF THE TH17 LINEAGE IN GLIOMA; BIOLOGIC IMPACT AND THERAPEUTIC POTENTIAL,Neuro-Oncology

Nathan Reynolds , Ashleigh Soedel , Emily Miller , David Ashley , Matthew Waitkus , Yiping He , Christopher Pirozzi ,

, v279-v279, 2023-11-01

13 - Data from CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP,

Casey J. Moure , Bill H. Diplas , Lee H. Chen , Rui Yang , Christopher J. Pirozzi , Zhaohui Wang , Ivan Spasojevic , Matthew S. Waitkus , Yiping He , Hai Yan ,

, 2023-04-03

14 - Data from CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP,

Casey J. Moure , Bill H. Diplas , Lee H. Chen , Rui Yang , Christopher J. Pirozzi , Zhaohui Wang , Ivan Spasojevic , Matthew S. Waitkus , Yiping He , Hai Yan ,

, 2023-04-03

15 - EPCO-43. STING EPIGENETIC SILENCING IN GBM: IMPLICATIONS FOR INFLAMING THE IMMUNE MICROENVIRONMENT AND DESIGNING COMBINATION THERAPIES,Neuro-Oncology

Justin Low , Michelle Bowie , Virginia Wertman , Eric Baker , Avani Mangoli , Emiley Gibson , Rodrigo de La Vega Gomar , Kevin Stevenson , Rebecca Fuller , Janell Hostettler , Michael Brown , Matthew Waitkus , Zachary Reitman , David Ashley ,

, v133-v133, 2023-11-01

16 - TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist,Acta Neuropathologica Communications

Cheng Xu , Heng Liu , Christopher J. Pirozzi , Lee H. Chen , Paula K. Greer , Bill H. Diplas , Liwei Zhang , Matthew S. Waitkus , Yiping He , Hai Yan ,

, 2021-11-03

Share Matthew's Profile